pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Peptide Therapeutic · news · pharmadog
← back to Peptide Therapeutic
News · Peptide Therapeutic
189
stories
3h
Study raises doubts about combining vaccine, monoclonal antibody to protect against malaria
stat
9h
STAT+: Lawmakers want U.S. biotech to outcompete China
stat
9h
STAT+: Peptide market poised to explode with new Hims and Noom launches
stat
10h
nChroma halves workforce, BioXcel lets execs go
biospace
21h
Ramping up: 3 biotechs growing their workforce after series C raises
biospace
1d
Hims launches popular peptides and other longevity treatments
endpoints
1d
Priavoid’s Alzheimer’s pill fails to prove efficacy in phase 2 trial
fiercebiotech
3d
Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
fiercebiotech
10d
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
biospace
10d
Argenx to buy peptide platform in potentially billion-dollar deal
biopharma dive
10d
Argenx buyout of peptide engine and Big Pharma favorite UNP could top $1B
biospace
10d
MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
fda medwatch
10d
Argenx inks $1.15B Unnatural Products buyout to expand in oral peptides
fiercebiotech
17d
FDA peptide policy risks undermining drug development and patient safety
biospace
20d
Once undruggable, the Wnt/B-catenin pathway shows increasing promise
biospace
21d
This Week at FDA: New ConOps for drug inspections, AI policy proposal, and more
raps
21d
HHS to allow compounders to make 6 unapproved peptides
biopharma dive
21d
STAT+: El-Sayed claps back at RFK Jr., and FDA’s ‘enforcement discretion’ on peptides
stat
21d
STAT+: HHS green lights six peptides, despite concerns from FDA scientists
stat
21d
Martin Kulldorff critiques scientific gatekeepers at NIH lecture
stat
21d
STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more
stat
21d
HHS clears compounding pharmacies to manufacture 6 unapproved peptides
biospace
22d
HHS will permit compounding of six peptides ahead of formal rulemaking
raps
22d
FDA revises guidance on essential drug delivery device performance
raps
22d
STAT+: HHS moves to allow compounding of some unapproved peptides
stat
22d
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
biospace
24d
Another autoimmune CAR-T death; Treasury zeroes in on China deals
biopharma dive
24d
Novel protein and peptide therapeutics
biopharma dive
27d
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
biospace
28d
This Week at FDA: Peptide dispute, clinical trial legislation, and more
raps
← prev
page 1 of 7
next →